Danaher Corporation $DHR Shares Sold by Wills Financial Group LLC

Wills Financial Group LLC reduced its holdings in shares of Danaher Corporation (NYSE:DHR) by 15.3% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 31,426 shares of the conglomerate’s stock after selling 5,682 shares during the quarter. Danaher accounts for about 2.5% of Wills Financial Group LLC’s investment portfolio, making the stock its 13th largest holding. Wills Financial Group LLC’s holdings in Danaher were worth $5,958,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also made changes to their positions in the stock. Elevated Capital Advisors LLC acquired a new position in Danaher during the 4th quarter worth $26,000. Hilton Head Capital Partners LLC acquired a new stake in shares of Danaher in the 4th quarter valued at about $27,000. Clal Insurance Enterprises Holdings Ltd lifted its position in shares of Danaher by 71.6% during the fourth quarter. Clal Insurance Enterprises Holdings Ltd now owns 127 shares of the conglomerate’s stock worth $29,000 after purchasing an additional 53 shares during the last quarter. JPL Wealth Management LLC acquired a new position in Danaher in the third quarter worth about $25,000. Finally, Main Street Group LTD acquired a new position in Danaher in the first quarter worth about $25,000. Institutional investors and hedge funds own 79.05% of the company’s stock.

Danaher Stock Performance

Shares of NYSE DHR opened at $192.52 on Friday. The company has a quick ratio of 1.52, a current ratio of 1.65 and a debt-to-equity ratio of 0.48. The firm’s 50-day moving average price is $185.05 and its two-hundred day moving average price is $197.07. Danaher Corporation has a 52-week low of $160.93 and a 52-week high of $242.80. The stock has a market capitalization of $135.34 billion, a P/E ratio of 34.20, a P/E/G ratio of 2.19 and a beta of 0.79.

Danaher (NYSE:DHR) last posted its earnings results on Tuesday, July 21st. The conglomerate reported $1.94 EPS for the quarter, beating the consensus estimate of $1.85 by $0.09. The company had revenue of $6.26 billion during the quarter, compared to analyst estimates of $6.12 billion. Danaher had a return on equity of 11.04% and a net margin of 15.95%.The business’s revenue was up 5.5% compared to the same quarter last year. During the same period in the prior year, the company earned $0.77 earnings per share. As a group, sell-side analysts forecast that Danaher Corporation will post 8.51 earnings per share for the current year.

Danaher Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Friday, June 26th will be given a dividend of $0.40 per share. The ex-dividend date is Friday, June 26th. This represents a $1.60 dividend on an annualized basis and a yield of 0.8%. Danaher’s payout ratio is currently 30.95%.

Wall Street Analysts Forecast Growth

DHR has been the topic of several research reports. DZ Bank initiated coverage on Danaher in a research note on Wednesday, June 3rd. They set a “buy” rating and a $210.00 price objective on the stock. Argus decreased their target price on Danaher from $265.00 to $230.00 and set a “buy” rating for the company in a research report on Friday, April 24th. HSBC lowered their price target on Danaher from $270.00 to $230.00 and set a “buy” rating for the company in a report on Wednesday, June 3rd. Evercore reissued an “outperform” rating and set a $230.00 price target on shares of Danaher in a research report on Monday, July 6th. Finally, Jefferies Financial Group restated a “buy” rating and set a $245.00 price objective on shares of Danaher in a research note on Tuesday, April 21st. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have issued a Hold rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $228.91.

Trending Headlines about Danaher

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Several commentary pieces say the post-earnings drop may have created a buying opportunity, with Barron’s arguing investors should not abandon Danaher (DHR) after the sharp reaction and suggesting the stock could rebound. Article: Don’t Quit on Danaher Stock After Horrific Earnings Reaction
• Positive Sentiment: One technical-market update said the selloff may be showing signs of capitulation, and noted some bullish trading activity in the shares, which could indicate downside pressure is easing. Article: Stock Of The Day: Is The Danaher Selloff Over?
• Positive Sentiment: Wall Street analysts still see meaningful upside from current levels, with one note highlighting a consensus price target implying about 32% potential gain and improving earnings estimate revisions. Article: Can Danaher (DHR) Climb 32.39% to Reach the Level Wall Street Analysts Expect?
• Neutral Sentiment: Danaher’s Q2 2026 earnings call transcript was published, giving investors a fresh look at management’s commentary and the company’s outlook, but the transcript itself does not change fundamentals. Article: Danaher (DHR) Q2 2026 Earnings Call Transcript
• Neutral Sentiment: Unusual options activity showed elevated put buying in Danaher (DHR), suggesting some traders are hedging for further downside or volatility after the earnings-driven move.
• Negative Sentiment: Recent coverage says the stock’s sharp decline was driven by Q2 results where a beat on earnings was overshadowed by bioprocessing weakness and analyst price-target cuts, which remain the main bearish overhang on the shares. Article: Stock Of The Day: Is The Danaher Selloff Over?

Danaher Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.